echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The application for the clinical trial of BC004 for injection, a subsidiary of Buchang Pharmaceutical, was accepted

    The application for the clinical trial of BC004 for injection, a subsidiary of Buchang Pharmaceutical, was accepted

    • Last Update: 2022-02-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 22, Buchang Pharmaceutical announced that the clinical trial application for "BC004 for injection" of its holding subsidiary Luzhou Buchang Bio-Pharmaceutical Co.


    BC004 for injection is a recombinant anti-HER2/CD3 humanized bispecific antibody drug, which is mainly used for the treatment of HER2-positive advanced solid tumors, including HER2-positive breast cancer, gastric cancer/gastroesophageal junction adenocarcinoma,


    As of December 31, 2021, Luzhou Buchang has invested approximately RMB 48.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.